Australian recommendations for the management of drug-resistant tuberculosis, 2023
DOI:
https://doi.org/10.33321/cdi.2023.47.48%20Abstract
-
Downloads
References
World Health Organization (WHO) Global Tuberculosis Programme. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment, 2022 update. Geneva: WHO; 15 December 2022. Available from: https://www.who.int/publications/i/item/9789240063129.
WHO Global Tuberculosis Programme. Rapid Communication: key changes to the treatment of drug-resistant tuberculosis. Geneva: WHO; 2 May 2022. Available from: https://www.who.int/publications/i/item/WHO-UCN-TB-2022-2.
WHO Global Tuberculosis Programme. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. Geneva: WHO; 15 June 2020. Available from: https://www.who.int/publications/i/item/9789240007048.
WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: WHO; 2019. Available from: https://apps.who.int/iris/handle/10665/311389.
Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10):e93–142. doi: https://doi.org/10.1164/rccm.201909-1874ST.
WHO Global Tuberculosis Programme. WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents. Geneva: WHO; 18 March 2022. Available from: https://www.who.int/publications/i/item/9789240046764.
The Sentinel Project on Pediatric Drug-Resistant Tuberculosis. Management of Drug-Resistant Tuberculosis in Children: A Field Guide. November 2021, Fifth edition. Boston: The Sentinel Project on Pediatric Drug-Resistant Tuberculosis; November 2021. Available from: http://sentinel-project.org/wp-content/uploads/2022/03/DRTB-Field-Guide-2021_v5.pdf.
Brode SK, Dwilow R, Kunimoto D, Menzies D, Khan FA. Canadian Tuberculosis Standards – 8th Edition, Chapter 8: Drug-resistant tuberculosis. Can J Respir. 2022;6(Suppl 1):109–128. doi: https://doi.org/10.1080/24745332.2022.2039499.
Nyang’wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z et al. A 24-week, all-oral regimen for rifampicin-resistant tuberculosis. N Engl J Med. 2022;387(25):2331–43. doi: https://doi.org/10.1056/NEJMoa2117166.
Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902. doi: https://doi.org/10.1056/NEJMoa1901814.
Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N et al. Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387(9):810–23. doi: https://doi.org/10.1056/NEJMoa2119430.
WHO Global Tuberculosis Programme. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. Geneva: WHO; 2008. Available from: https://apps.who.int/iris/handle/10665/43965.
WHO Global Tuberculosis Programme. Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. Geneva: WHO; 15 February 2011. Available from: https://www.who.int/publications/i/item/9789241501583.
WHO Global Tuberculosis Programme. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: WHO; 16 September 2016. Available from: https://www.who.int/publications/i/item/9789241549639.
WHO Global Tuberculosis Programme. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27–29 October 2020. Geneva: WHO; 22 January 2021. Available from: https://www.who.int/publications/i/item/9789240018662.
WHO Global Tuberculosis Programme. Global tuberculosis report 2022. Geneva: WHO; 27 October 2022. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022.
WHO Global Tuberculosis Programme. Global tuberculosis report 2020. Geneva: WHO; 15 October 2020. Available from: https://www.who.int/publications/i/item/9789240013131.
Australian Government Department of Health and Aged Care, National Notifiable Diseases Surveillance System (NNDSS). Tuberculosis notifications, 2019–2022. [Unpublished data.] Canberra: Australian Government Department of Health and Aged Care. [Accessed on 16 June 2023.]
Bastian I, Shephard L, Lumb R, National Tuberculosis Advisory Committee. Revised guidelines for Australian laboratories performing mycobacteriology testing. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.2.
van der Werf MJ, Hollo V, Ködmön C, Dara M, Catchpole M. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J. 2017;49(3):1601992. doi: https://doi.org/10.1183/13993003.01992-2016.
Tsang CA, Shah N, Armstrong LR, Marks SM. Eligibility for a shorter treatment regimen for multidrug-resistant tuberculosis in the United States, 2011–2016. Clin Infect Dis. 2019;70(5):907–16. doi: https://doi.org/10.1093/cid/ciz263.
Lange C, Duarte R, Fre´chet-Jachym M, Guenther G, Guglielmetti L, Olaru ID et al. Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe. Am J Respir Crit Care Med. 2016;194(8):1029–31. doi: https://doi.org/10.1164/rccm.201606-1097LE.
Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, Rieder HL. Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. Int J Tuberc Lung Dis. 2018;22(3):239–45. doi: https://doi.org/10.5588/ijtld.17.0660.
Mirzayev F, Viney K, Linh NN, Gonzalez-Angulo L, Gegea M, Jaramillo E et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. 2021;57(6):2003300. doi: https://doi.org/10.1183/13993003.03300-2020.
Gibson J, Donnan E, Eather G. Management of rifampicin mono-resistant tuberculosis in Queensland, Australia: a retrospective case series. Respirol Case Rep. 2018;6(8):e00366. doi: https://doi.org/10.1002/rcr2.366.
Toman K, Frieden TR, WHO. Toman’s tuberculosis : case detection, treatment, and monitoring : questions and answers / edited by T. Frieden, 2nd ed. Geneva: WHO; 2004. Available from: https://apps.who.int/iris/handle/10665/42701.
WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO; 2014. Available from: https://apps.who.int/iris/handle/10665/130918.
Curry International Tuberculosis Center (CITC), California Department of Public Health Tuberculosis Control Branch. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians,3rd edition/2022 Updates. San Francisco: University of California San Francisco, CITC; December 2022. Available from: https://www.currytbcenter.ucsf.edu/products/view/drug-resistant-tuberculosis-survival-guide-clinicians-3rd-edition.
WHO Regional Office for Europe. The role of surgery in the treatment of pulmonary tuberculosis and multidrug- and extensively drug-resistant tuberculosis. Geneva: WHO; 2014.
Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY et al. Surgery as an adjunctive treatment for multidrug-resistant tuberculosis: an individual patient data meta-analysis. Clin Infect Dis. 2016;62(7):887–95. doi: https://doi.org/10.1093/cid/ciw002.
Marrone MT, Venkataramanan V, Goodman M, Hill AC, Jereb JA, Mase SR. Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17(1):6–16. doi: https://doi.org/10.5588/ijtld.12.0198.
WHO Global Tuberculosis Programme. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: WHO; 15 December 2022. Available from: https://www.who.int/publications/i/item/9789240065116.
Upton CM, Steele CI, Maartens G, Diacon AH, Wiesner L, Dooley KE. Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). J Antimicrob Chemother. 2022;77(6):1720–4. doi: https://doi.org/10.1093/jac/dkac067.
Tucker EW, Pieterse L, Zimmerman MD, Udwadia ZF, Peloquin CA, Gler MT et al. Delamanid central nervous system pharmacokinetics in tuberculous meningitis in rabbits and humans. Antimicrob Agents Chemother. 2019;63(10):e00913-19. doi: https://doi.org/10.1128/AAC.00913-19.
Alffenaar JWC, Akkerman OW, Kim HY, Tiberi S, Migliori GB. Precision and personalized medicine and anti-TB treatment: is TDM feasible for programmatic use? Int J Infect Dis. 2020;92S:S5–9. doi: https://doi.org/10.1016/j.ijid.2020.01.041.
Sturkenboom MG, Märtson AG, Svensson EM, Sloan DJ, Dooley KE, van den Elsen SHJ et al. Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs. Clin Pharmacokinet. 2021;60(6):685–710. doi: https://doi.org/10.1007/s40262-021-00997-0.
Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, van der Zalm MM et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis. 2021;25(10):797–813. doi: https://doi.org/10.5588/ijtld.21.0425.
WHO. WHO guidelines on tuberculosis infection prevention and control, 2019 update. Geneva: WHO; 2019. Available from: https://apps.who.int/iris/handle/10665/311259.
Migliori GB, Nardell E, Yedilbayev A, D’Ambrosio L, Centis R, Tadolini M et al. Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. Eur Respir J. 2019;53(6):1900391. doi: https://doi.org/10.1183/13993003.00391-2019.
Marks SM, Mase SR, and Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017;64(12):1670–7. doi: https://doi.org/10.1093/cid/cix208.
Linh NN, Viney K, Gegia M, Falzon D, Glaziou P, Floyd K et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update. Eur Respir J. 2021;58(2):2100804. doi: https://doi.org/10.1183/13993003.00804-2021.
Fox GJ, Menzies D. A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis. Infect Dis Ther. 2013;2(2):123–44. doi: https://doi.org/10.1007/s40121-013-0009-3.
De Bus L, Depuydt P, Libbrecht L, Vandekerckhove L, Nollet J, Benoit D et al. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol. 2010;6(3):322–6. doi: https://doi.org/10.1007/s13181-010-0047-0.
Luque S, Muñoz-Bermudez R, Echeverría-Esnal D, Sorli L, Campillo N, Martínez-Casanova J et al. Linezolid dosing in patients with liver cirrhosis: standard dosing risk toxicity. Ther Drug Monit. 2019;41(6):732–9. doi: https://doi.org/10.1097/FTD.0000000000000665.
Published
How to Cite
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
